Symposium 8 Novel therapeutic strategy for AML

[SY8-4] CPX-351 (Vyxeos): From early skepticism to FDA approval

Bruno C. Medeiros (Medicine/Hematology, Stanford University, United States of America)

Bruno C. Medeiros, MD is an associate professor of medicine, division of hematology at Stanford University. He is also the medical director of Cancer Center infusion treatment area services at Stanford Comprehensive Cancer Center and medical director of the inpatient hematology service. Dr. Medeiros graduated from the Universidade Federal do Parana with a medical degree, in 1998. He completed his post-graduate training at the University of Colorado in Denver and the Princess Margaret Hospital in Toronto (Acute leukemia fellowship). Dr. Medeiros’ clinical interests include management of advanced hematologic malignancies, including AML, ALL, MDS and CML. His clinical research interest focuses on population-based research in AML and the development of novel therapeutic regimens for patients with acute myeloid leukemia. He is the leader in several institutional investigator initiated clinical trials, active investigator in collaborative multi-institutional clinical studies and an active member of the SWOG acute leukemia panel. Dr. Medeiros has authored more than 120 peer-reviewed manuscripts. Dr. Medeiros has served as the track leader for ASCO meeting Leukemia, Myelodysplasia and Transplantation scientific review subcommittee, he functions as the Associate Editor of the Leukemia Panel for Cancer.Net, he is a member of the editorial board for Leukemia Research and serves as a reviewer for several specialized journals, such as Blood, Leukemia, Haematologica and Cancer, among others.